NCT03889366View on ClinicalTrials.gov

Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

April 15, 2019

Study Completion Date

April 30, 2019

Conditions
Healthy
Interventions
DRUG

Aprepitant 125 mg

Single dose in the fasted state during treatment period 1,2 or 3

Trial Locations (1)

NG11 6JS

Quotient Sciences Limited, Nottingham

Sponsors
All Listed Sponsors
lead

Nuformix Technologies Limited

INDUSTRY

NCT03889366 - Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers | Biotech Hunter | Biotech Hunter